Andere Kunden interessierten sich auch für
![Oxidative stress and antioxidant status in Saudi asthmatic patients]( "Oxidative stress and antioxidant status in Saudi asthmatic patients")
Oxidative stress and antioxidant status in Saudi asthmatic patients32,99 €![Serum Vitamin D level in Children with Asthma: A Case Control Study]( "Serum Vitamin D level in Children with Asthma: A Case Control Study")
Serum Vitamin D level in Children with Asthma: A Case Control Study26,99 €![Efficacia del Montelukast con i corticosteroidi nei pazienti asmatici]( "Efficacia del Montelukast con i corticosteroidi nei pazienti asmatici")
Efficacia del Montelukast con i corticosteroidi nei pazienti asmatici23,99 €![How about blowing to make the asthma go away?]( "How about blowing to make the asthma go away?")
How about blowing to make the asthma go away?26,99 €![Finally an effective treatment for allergic diseases!]( "Finally an effective treatment for allergic diseases!")
Finally an effective treatment for allergic diseases!29,99 €![Translational Neuroimmunology in Multiple Sclerosis]( "Translational Neuroimmunology in Multiple Sclerosis")
Translational Neuroimmunology in Multiple Sclerosis79,99 €![To evaluate the efficacy of Tila e Hadaf in the management of ED]( "To evaluate the efficacy of Tila e Hadaf in the management of ED")
To evaluate the efficacy of Tila e Hadaf in the management of ED32,99 €
Asthma is an inflammatory disease characterized by recurrent attacks of breathlessness and wheezing. Inhaled corticosteroids (ICS) play an important role in the management of asthma. Reduction of ICS dose with any other drug combination may therefore be of clinical significance. A total of 118 Patients with mild to moderate asthma were enrolled in this randomized controlled study from the pulmonology/ medicine unit in the tertiary care hospital. Patients were randomized into two groups viz., control group (n=59) and the treatment group (n=59). Control group patients received budesonide 800 mg twice a day and the treatment patients received 400 mg budesonide twice a day+ Montelukast 10 mg. Pulmonary function test was assessed at the baseline and on follow up days. No significant differences was observed with respect to socioeconomic and educational status of patients between control and treatment groups. Improvement observed was more in control group value (43%) than in treatment group value (25%). Even though 12% FEV1 improvement were observed, the rate of improvement were not significant (p0.5). There is no serious adverse drug reaction among the tested groups. The study conclud